GLP-1 receptor agonist lixisenatide approved for type 2 diabetes
The Food and Drug Administration has approved the once-daily injectable lixisenatide, a glucagonlike peptide-1 (GLP-1) receptor agonist, as an adjunct to diet and exercise for improved glycemic...
Source: Clinical Endocrinology News - Category: Endocrinology Source Type: news
More News: Diabetes | Diabetes Type 2 | Endocrinology | Food and Drug Administration (FDA) | Nutrition | Sports Medicine